scientist holding test tube

New discovery may result in a new class of diabetes drugs.

Research led by The Ohio State University Wexner Medical Center and College of Medicine identified a new compound that might serve as a basis for developing a new class of drugs for diabetes.

Study findings are published online in the journal Nature Chemical Biology.

The adenosine monophosphate-activated protein kinase (Ampk) is a crucial enzyme involved in sensing the body’s energy stores in cells. Impaired energy metabolism is seen in obesity, which is a risk factor for diabetes. Some medications used to treat diabetes, such as metformin, work by increasing the activity of Ampk.


New histopathology tech does away with staining.
Histology is the study of biological tissues at a microscopic level. Also …
Michio Kaku’s “The God Equation” is everything a pop science book should be.
To the uninitiated, books about string theory can feel impenetrable, if not …
Annual wildfires are ruining air quality in the West.
From the Pacific Northwest to the Rocky Mountains, summers in the West …
Anti-viral T-cells can help after stem cell therapy
 A Phase II trial led by researchers at The University of Texas …

“In our study, we discovered a protein that is involved in removing Ampk from cells called Fbxo48. We designed and tested a compound termed, BC1618, that blocks Fbxo48 and was much more potent than metformin in increasing Ampk function. BC1618 improved responses to insulin, a measure of effectiveness for diabetes medicines, in obese mice,” said Dr. Rama K. Mallampalli, senior author and chair of the department of internal medicine at Ohio State.

Mallampalli began this research at The University of Pittsburgh before joining Ohio State, and continued collaborating with researchers there to complete the study.

“This study builds on our prior research to understand how critical proteins in the body are removed or degraded. The research team had previously designed and produced a family of anti-inflammatory drugs that are FDA approved and are poised to enter Phase 1 studies,” Mallampalli said. “Using this new compound as a backbone, our team including Dr. Bill Chen and Dr. Yuan Liu at Pittsburgh will make other compounds that are more potent and safe in animal models and then test them in diabetes animal models. Eventually we aim to obtain FDA approval for human testing.”


Processing…
Success! You're on the list.

Leave a Reply

%d bloggers like this: